Eric Severson, MD, PhD, MMSc

Dr. Eric Severson is a board-certified anatomic and hematopathologist with expertise in hematologic malignancies, molecular pathology, computational biology, comprehensive genomic profiling, and precision medicine.  Dr. Severson earned his M.D. and Ph.D. in molecular biology and genetics from Emory University Medical School and Graduate School of Biomedical Sciences, followed by residency training at Brigham and Women’s Hospital.

Shakti Ramkissoon, MD, PhD

Dr. Shakti Ramkissoon is board certified in anatomic pathology and neuropathology with expertise in adult and pediatric brain tumors. He obtained his MD/PhD from Rutgers -- New Jersey Medical School, concentrating on cancer stem cell biology. Dr. Ramkissoon then completed an anatomic pathology residency and neuropathology fellowship training at Brigham and Women's Hospital (BWH), Boston, Mass. After completing his clinical training, Dr.

Labcorp announces 2022 fourth quarter and full-year results

Company Provides 2023 Guidance Revenue: Q4 of $3.7 billion , versus $4.1 billion last year; Full year of $14.9 billion , versus $16.1 billion last year Diluted EPS: Q4 of $0.86 , versus $5.75 last year; Full year of $13.97 , versus $24.39 last year Adjusted EPS: Q4 of $4.14 , versus $6.77 last

Take control of your health with routine checkups and preventative care

Throughout the pandemic, wearing real pants and getting haircuts weren't the only things we put off. Basic health appointments and yearly exams got rescheduled, and even our routine care that catches things as serious as cancer got put on hold.

Rebecca Previs, MD, MS

Dr. Rebecca Previs is a board-certified gynecologic oncologist with expertise in women’s health, precision medicine and early phase clinical trials. Dr. Previs prioritizes her research in evaluating the immune contexture of molecular characterized uterine cancers and how biomarkers can inform prognosis and treatment response in patients with medically managed uterine cancers.

Heidi Ko, DO

Dr. Heidi Ko is board certified in Internal Medicine, Hematology and Medical Oncology.  She received her medical degree from Rowan University School of Osteopathic Medicine in Stratford, NJ and her Internal Medicine training at McGovern Medical School at UT Health in Houston, TX.  Dr. Ko completed her Hematology and Oncology fellowship training at Montefiore Medical Center/Albert Einstein College of Medicine in Bronx, NY. After her fellowship, Dr.

Maureen Cooper

Maureen Cooper has a degree in Bioinformatics from the City University of New York and has spent over 15 years in the molecular diagnostics space. Her experience includes academic research at the University of Pittsburgh as well as industry where she has held multiple Commercial and Medical Affairs roles. Over the course of her career, Maureen has focused on educating Oncologists and Pathologists on the value of biomarker testing for cancer patients and building testing pathways for Oncology programs through education and collaboration.

Labcorp unveils new name for future independent clinical development business: Fortrea

Fortrea Will Become a Leading, Pure-play CRO Focused on Driving Innovation and Improving Patient Outcomes Worldwide Spin-off Remains on Track to Be Completed in Mid-2023 BURLINGTON, N.C. --(BUSINESS WIRE)--Feb. 9, 2023-- Labcorp (NYSE: LH), a leading global life sciences company, today announced

The clinical relevance of anti-DFS70 autoantibodies

 

Presentation on the use of the anti-DFS70 antibodies to help identify ANA-positive individuals who do not have an ANA-associated autoimmune disease (AARD), especially in the absence of significant clinical findings.

Speaker

Vincent Ricchiuti, PhD Laboratory Director and Discipline Director in Immunology, Labcorp